Breaching the Wall

Editor’s choice in immunology

By | December 1, 2011

Two differentially labeled populations of Pseudomonas aeruginosa MICHELE LEROUX, UNIVERSITY OF WASHINGTON

The paper

A.B. Russell et al., “Type VI secretion delivers bacteriolytic effectors to target cells,” Nature, 475:343-47, 2011. Free F1000 Evaluation

The finding

As a major component of the bacterial cell wall, peptidoglycan is both part of a bacterium’s defense strategy and its Achilles heel. Joseph Mougous at the University of Washington and colleagues showed that the bacterium Pseudomonas aeruginosa can oust competitors by using the multiprotein type VI secretion apparatus (T6SS) to degrade a rival’s peptidoglycan. The “elegant” study “made sure every experiment that you’d imagine doing was done,” says Victor DiRita from the University of Michigan.

The contributor

Previously, researchers thought that T6SS was primarily used to target eukaryotic cells. However, when Mougous and colleagues cultured the bacterium with Pseudomonas putida, P. aeruginosa secreted enzymes that broke the peptidoglycan bonds of the P. putida cell wall. But because P. putida’s peptidoglycan is not exposed on its surface, as it is in gram-positive bacteria, the T6SS must inject the toxic proteins beneath the cell’s outer membrane into the periplasmic space where the peptidoglycan resides.

The shield

The researchers showed that the bacterium also produces proteins that shield it from its own poison, though it’s not yet clear how these proteins function. Lacking these immunity proteins severely impaired the growth of other P. aeruginosa in the presence of an active T6SS system.

The implications

The results raise questions about why the “exquisite delivery mechanism” evolved the way it did, DiRita said, and could reveal ways to target this disease-causing pathogen in humans.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham